Follow
Qlife Holding AB
Nasdaq First North Sweden (Sweden)
Qlife’s vision is to facilitate regular blood biomarker testing from home environment. We aim to make blood sampling convenient, cheap, fast, accessible and accurate resulting in more frequent blood testing to gain insight into personal health, with increased possibility for earlier discovery of illnesses. Our product is an integrated platform consisting of a small home device, disposable capsules each a test for a specific biomarker, and a digital infrastructure that shares data with patient journal or hos Qlife’s vision is to facilitate regular blood biomarker testing from home environment. We aim to make blood sampling convenient, cheap, fast, accessible and accurate resulting in more frequent blood testing to gain insight into personal health, with increased possibility for earlier discovery of illnesses. Our product is an integrated platform consisting of a small home device, disposable capsules each a test for a specific biomarker, and a digital infrastructure that shares data with patient journal or hospital platform.

Read more

Sector:
HEALTH CARE
>
Health Care Equipment & Services
News
Nothing to display for this company
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
QLIFE
SE0013486552
Nasdaq First North Sweden
Sweden (SE)
Details of share in Qlife Holding AB with ticker QLIFE
Status
Inactive
Order book id
Amount of instruments
4 066 000
Par value
8,000.0000
Market cap
Currency
SEK
First trading date
02 Mar 2020
Terms
Type
Price
Pre-money valuation
Time
IPO
12.30 SEK
82.4M SEK
20 Jan - 07 Feb 2020
IPO in Qlife Holding AB
Market
Nasdaq First North Sweden
Subscription period
20 Jan - 07 Feb 2020
Subscription price
12.30 SEK
Price per share
12.30 SEK
Target to raise
50 011 800 SEK
Types
Share issue
Pre-money valuation
82 400 000 SEK
Subscription block size
Minimum subscription
Record date
Offer status
Closed
Listing status
Upcoming
First trading date
02 Mar 2020
Issue terms
The offer is aimed at both institutional investors and the general public.
Comments for offer & related information
The company shall issue a maximum of 4 066 000 units + 406 600 units in terms of over-allotment. The offer is SEK 50 million and in the event of major interest, an over-allotment option of SEK 5 million can also be used. The offer is covered by subscription commitments amounting to approximately SEK 35 million. Each unit contains one (1) share and one (1) free subscription option of series TO1. Two (2) warrants of the TO1 series give the right to subscribe for one (1) new share in the Company during the period 3 - 31 May 2021 at a subscription price of SEK 17.50.
Type
Ticker
ISIN
Market
OPTION
QLIFE TO1
SE0013719333
Nasdaq First North Sweden
Sweden (SE)
Details of option in Qlife Holding AB with ticker QLIFE TO1
Status
Inactive
Order book id
Amount of instruments
Market cap
Currency
SEK
First trading date
02 Mar 2020
Terms
Two (2) warrants of the TO1 series give the right to subscribe for one (1) new share
Type
Price
Pre-money valuation
Time
Exercise
17.50 SEK
-
03 May - 31 May 2021
Option exercise terms for QLIFE TO1
Market
Nasdaq First North Sweden
Exercise period(s)
03 May - 31 May 2021
Exercise price
17.50 SEK
Status
Upcoming
Issue terms
Two (2) warrants of the TO1 series give the right to subscribe for one (1) new share
People
Thomas Warthoe
CEO
Mette Gross
Chairman of the board
Niklas Marschall
Board member
John Moll
Board member
Company Details
Sector
HEALTH CARE

Address
Hamntorget 3
Zip code
252 21
City/district
Helsingborg
Country
Sweden (SE)
Registration number
559224-8040
LEI code
Qlife Holding AB
First trade date
02 Mar 2020
Registration date
31 Oct 2019
Short name
Qlife Holding

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date